RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.24.20138875
DO 10.1101/2020.06.24.20138875
A1 Pagani, Gabriele
A1 Conti, Federico
A1 Giacomelli, Andrea
A1 Bernacchia, Dario
A1 Rondanin, Rossana
A1 Prina, Andrea
A1 Scolari, Vittore
A1 Gandolfi, Cecilia Eugenia
A1 Castaldi, Silvana
A1 Marano, Giuseppe
A1 Ottomano, Cosimo
A1 Boracchi, Patrizia
A1 Biganzoli, Elia
A1 Galli, Massimo
YR 2020
UL http://medrxiv.org/content/early/2020/06/24/2020.06.24.20138875.abstract
AB Castiglione D’Adda is one of the towns earlier and more severely affected by the SARS-CoV-2 epidemic in Lombardy. In a mass screening involving 4174 out of about 4550 total inhabits, significant age-related differences in anti SARS-CoV-2 IgG seroprevalence were found, with the lowest prevalence in the youngest inhabitants.Article Summary Line In one of the areas of first expansion of the epidemic in Italy IgG seroprevalence for SARS-CoV-2 increases with age, possibly suggesting age related differences in susceptibility to infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the non-conditioning economical support from CISOM (Corpo Italiano di Soccorso dell'Ordine di Malta), Banca Mediolanum s.p.a., Fondazione Rava and FC Internazionale Milano.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by University of Milan's Ethical Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesComplete dataset is available on a reasonable request.